Recombinant Cancer pagurus Mandibular organ-inhibiting hormone 2

What is Mandibular Organ-Inhibiting Hormone 2 and how does it differ from MOIH-1?

Mandibular Organ-Inhibiting Hormone 2 (MOIH-2) is a 78-residue neuropeptide belonging to the crustacean hyperglycemic hormone (CHH) family that negatively regulates methyl farnesoate (MF) production by the mandibular organs in crustaceans. MOIH-2 differs from MOIH-1 by a single amino acid in the mature peptide sequence and one in the putative signal peptide region . Both isoforms were isolated from the sinus glands of Cancer pagurus and share the fundamental function of inhibiting MF synthesis, which is the unepoxidized analog of insect juvenile hormone-III (JH-III) . This structural difference, though minimal, may contribute to subtle functional variations in their regulatory capacities within the endocrine system of the crab.

How is the MOIH-2 gene organized in the Cancer pagurus genome?

The MOIH-2 gene in Cancer pagurus exhibits a distinct genomic organization characterized by:

• A structure containing three exons and two introns, with the exon-intron boundaries following Chambon's rule (GT-AG) for splice donor and acceptor sites .

• The first intron occurs within the signal peptide region, while the second intron is located in the coding region of the mature peptide .

• Unlike MOIH-1, which is clustered with the MIH gene within 6.5kb in a convergently transcribed arrangement, the MOIH-2 gene is not closely linked to an MIH gene .

• Genomic Southern blot analysis has revealed that the Cancer pagurus genome contains approximately 10 copies of the MOIH gene, with at least three copies of the MOIH genes identified through library screening .

This genomic organization provides insight into the evolutionary relationship between MOIH and MIH genes, suggesting they represent an example of evolutionary divergence of crustacean hormones .

What is the molecular structure of recombinant MOIH-2 and how does it compare to the native hormone?

The recombinant MOIH-2 is designed to replicate the 78-residue structure of the native mature hormone. Full-length clones of MOIH-2 encode a 34-residue putative signal peptide followed by the mature 78-residue MOIH-2 sequence . The native hormone contains six conserved cysteine residues that form three disulfide bridges, which are critical for maintaining the tertiary structure and biological activity of the hormone .

When producing recombinant MOIH-2, researchers must ensure proper disulfide bond formation to maintain the native conformation. Successful recombinant expression typically requires specialized expression systems that facilitate correct post-translational modifications, particularly the formation of disulfide bonds. Comparative analyses between native and recombinant MOIH-2 often employ techniques such as circular dichroism spectroscopy and bioactivity assays to confirm structural and functional integrity.

Where is MOIH-2 naturally expressed in Cancer pagurus?

Northern blot analysis of various tissues has demonstrated that MOIH expression is strictly confined to the X-organ, a cluster of perikarya within the eyestalk neural ganglia of Cancer pagurus . This localization is consistent with the neuroendocrine function of MOIH-2 as part of the X-organ-sinus gland (XO-SG) complex. Immunohistochemical studies across multiple Cancer species have shown conserved differential distribution patterns of CHH family peptides, with MOIH being found in specific sets of neurons within the XO-SG system .

In Cancer pagurus and other related species, MOIH is synthesized in the X-organ neurons, transported along axonal projections, and stored in the sinus gland terminals prior to release into the hemolymph . The precise neuronal localization within the XO-SG complex is significant, as MOIH and MIH are co-localized in a different set of cell bodies than those containing CHH and CPRP (CHH precursor-related peptide), suggesting specialized production and release mechanisms for different hormone families .

How do environmental factors influence MOIH-2 expression and release?

While the search results do not provide direct information on environmental regulation of MOIH-2 specifically, we can draw parallels from studies on related hormones in the CHH family. For instance, research on CHH in Cancer pagurus demonstrates that environmental stressors significantly impact hormone release patterns. During emersion stress (exposure to air), CHH levels increase dramatically in the hemolymph, from almost undetectable levels to around 17 pmol/l within the first hour, and further increasing to approximately 30 pmol/l after 4 hours .

This stress-induced hormone release pattern suggests that environmental factors likely play a crucial role in regulating the release of other XO-SG neuropeptides, including MOIH-2. Potential environmental regulators may include:

• Hypoxia or changes in dissolved oxygen levels

• Temperature fluctuations

• Salinity changes

• Photoperiod alterations

• Food availability

Methodological approach to studying environmental regulation would include controlled laboratory experiments varying these parameters individually and measuring MOIH-2 expression levels through qPCR and protein levels through immunoassays.

What expression systems are most effective for producing functional recombinant MOIH-2?

For successful production of functional recombinant MOIH-2, expression systems must facilitate proper folding and disulfide bond formation. Based on research with similar crustacean neuropeptides, the following expression systems have proven effective:

• Bacterial systems with specialized strains: E. coli strains engineered for disulfide bond formation (e.g., Origami, SHuffle) can be used with periplasmic targeting sequences to enhance proper folding.

• Yeast expression systems: Pichia pastoris and Saccharomyces cerevisiae offer eukaryotic post-translational modification capabilities and secretory pathways that support disulfide bond formation.

• Insect cell expression systems: Baculovirus-infected insect cells (Sf9, Sf21, or High Five) provide a more evolutionary proximate environment for arthropod hormone production.

When designing expression constructs, researchers should include the coding sequence for the mature 78-residue MOIH-2 peptide with appropriate affinity tags for purification . Codon optimization for the selected expression host is essential to enhance translation efficiency. For functional validation, the recombinant hormone should be tested in bioassays measuring inhibition of methyl farnesoate production by mandibular organs in vitro.

What purification strategies yield the highest purity and biological activity for recombinant MOIH-2?

Effective purification strategies for recombinant MOIH-2 should preserve the native conformation and biological activity of the hormone. Based on approaches used for similar neuropeptides, a multi-step purification protocol is recommended:

• Initial capture: Affinity chromatography using tags (His-tag, GST, etc.) engineered into the recombinant construct.

• Intermediate purification: Ion exchange chromatography exploiting the predicted isoelectric point of MOIH-2.

• Polishing step: Reversed-phase high-performance liquid chromatography (RP-HPLC) similar to that used for native MOIH-2 isolation from sinus gland extracts .

• Tag removal: If a cleavable tag was used, enzymatic removal followed by a second affinity step to separate the tag from the purified hormone.

The biological activity of purified recombinant MOIH-2 should be assessed through mandibular organ culture assays measuring the inhibition of methyl farnesoate synthesis and farnesoic acid O-methyl transferase activity . Comparison with native hormone or sinus gland extracts serves as a benchmark for functional validation.

How can researchers effectively evaluate the biological activity of recombinant MOIH-2?

To evaluate the biological activity of recombinant MOIH-2, researchers should employ both in vitro and in vivo approaches:

In vitro bioassays:

• Mandibular organ explant culture: Measuring the inhibition of methyl farnesoate (MF) synthesis in isolated mandibular organs. This is considered the gold standard for MOIH activity assessment .

• Farnesoic acid O-methyl transferase (FAMeT) activity assay: Quantifying the enzymatic activity in mandibular organ homogenates after exposure to recombinant MOIH-2 .

• Receptor binding assays: Using putative MOIH receptors, which are likely G protein-coupled receptors (GPCRs) similar to those identified for related hormones in other crustacean species .

In vivo approaches:

• Hemolymph MF level measurement: Administering recombinant MOIH-2 to eyestalk-ablated crabs (to remove endogenous hormone sources) and measuring changes in circulating MF levels using gas chromatography-mass spectrometry .

• Physiological response assessment: Monitoring developmental and reproductive parameters in response to hormone administration.

Researchers should note that in vivo testing of purified MOIH-1 and MOIH-2 has previously shown limited effects compared to whole sinus gland extracts, suggesting potential differences between recombinant and native hormones or the requirement for additional cofactors .

What are the contradictory findings regarding MOIH-2 function and how can these be resolved experimentally?

A significant contradiction in MOIH research concerns the differential effectiveness of purified MOIH peptides in vitro versus in vivo. While isolated MOIH-1 and MOIH-2 effectively inhibit MF synthesis by mandibular organs in vitro, they show limited activity when administered in vivo, unlike whole sinus gland extracts that produce robust inhibition (60-80% reduction in hemolymph MF levels) .

This discrepancy suggests several hypotheses:

• Cofactor requirement: MOIH may require additional factors present in sinus gland extracts for full in vivo activity.

• Stability issues: Recombinant or purified MOIH may be rapidly degraded or cleared from circulation in vivo.

• Indirect regulation: Some sinus gland compounds may affect the mandibular organ indirectly through intermediate pathways.

• Receptor differences: There may be differences in receptor binding or signaling between in vitro and in vivo contexts.

To resolve these contradictions experimentally, researchers could:

• Conduct HPLC fractionation of sinus gland extracts followed by bioassays to identify additional bioactive components .

• Perform hemolymph clearance studies to determine the half-life of recombinant MOIH-2 in vivo, similar to CHH clearance studies .

• Investigate potential intermediate signaling pathways by examining changes in second messenger systems (cAMP, cGMP, Ca2+) in target tissues.

• Characterize and compare MOIH receptor expression and binding properties in isolated mandibular organs versus in vivo contexts.

How can recombinant MOIH-2 be used to identify and characterize its receptor(s)?

The identification and characterization of MOIH-2 receptors represent a critical frontier in understanding the hormone's signaling mechanisms. Based on research with related hormones, several approaches can be employed:

• Candidate receptor approach: Recent genomic and transcriptomic analyses have identified putative G protein-coupled receptors (GPCRs) for CHH family hormones in various crustacean species . For example, in the swimming crab Portunus trituberculatus, five GPCRs were identified as potential CHH receptors. These receptors were divided into three groups, with one group comprising two contiguous genomic position GPCRs primarily expressed in the hepatopancreas . Similar approaches can identify candidate MOIH-2 receptors in Cancer pagurus.

• Functional expression systems: Candidate receptors can be expressed in heterologous systems (e.g., HEK293 cells, Xenopus oocytes) for binding and activation studies with recombinant MOIH-2.

• Reporter gene assays: Coupling receptor activation to reporter systems measuring second messenger (cAMP, Ca2+) production can quantify receptor activation.

• Photoaffinity labeling: Modified recombinant MOIH-2 with photoactivatable crosslinkers can be used to identify binding partners in mandibular organ membrane preparations.

• CRISPR-Cas9 gene editing: In species amenable to genetic manipulation, knockout or knockdown of candidate receptors can validate their role in MOIH-2 signaling.

The identification of MOIH-2 receptors would significantly advance our understanding of the hormone's mechanism of action and could reveal tissue-specific targets beyond the mandibular organ.

What is the relationship between MOIH-2 and other members of the CHH family in terms of evolution and function?

Evolutionary and functional relationships within the CHH family provide critical insights into hormone specialization and conservation. The CHH family is divided into two subfamilies: type I (CHH) and type II (MIH, VIH/GIH, and MOIH) . Several lines of evidence illuminate these relationships:

• Genetic clustering: Genomic analysis reveals that MOIH-1 and MIH genes are clustered within 6.5kb and convergently transcribed, while MOIH-2 is not closely linked to an MIH gene . This suggests differential evolutionary pressures on these genes.

• Gene structure conservation: All CHH family members in Cancer pagurus share a three-exon, two-intron structure with conserved exon-intron boundaries, indicating common ancestry .

• Differential tissue distribution: Immunohistochemical studies across seven Cancer species show conserved differential distribution patterns of CHH family peptides across neuroendocrine sites: CHH, CPRP, MIH, and MOIH in the XO-SG; CHH, CPRP, and MOIH in the pericardial organ (PO); and MOIH in the anterior cardiac plexus (ACP) .

• Cellular co-localization patterns: Within the XO-SG complex, CHH and CPRP occur in one set of neurons, while MIH and MOIH are co-localized in a different set of neurons, suggesting functional specialization .

• Evolutionary relationships to insect peptides: The discovery of ion transport peptide (ITP) in insects expanded the known members of the CHH superfamily, revealing that these hormones are not restricted to crustaceans . ITP-like peptides have also been found in crabs, primarily expressed in the eyestalk .

These relationships suggest that while sharing common ancestry, CHH family members have undergone functional specialization, with MOIH-2 evolving specific roles in regulating methyl farnesoate synthesis.

What experimental design is optimal for studying the effects of recombinant MOIH-2 on gene expression in target tissues?

To comprehensively investigate the effects of recombinant MOIH-2 on gene expression in target tissues, researchers should consider the following experimental design:

Study Design:

• Treatment groups:

  • Control (vehicle only)

  • Recombinant MOIH-2 (multiple concentrations)

  • Native sinus gland extract (positive control)

  • Heat-inactivated recombinant MOIH-2 (negative control)

• Time course:

  • Short-term effects (0.5, 1, 3, 6 hours)

  • Long-term effects (12, 24, 48 hours)

• Target tissues:

  • Primary: Mandibular organs

  • Secondary: Hepatopancreas, gonads, epidermis, nervous tissues

Methodological Approaches:

• RNA-Seq analysis: For global transcriptome profiling to identify all genes affected by MOIH-2 treatment.

• Real-time qPCR: For targeted validation of specific candidate genes, particularly those involved in methyl farnesoate synthesis pathway (e.g., farnesoic acid O-methyl transferase).

• Protein expression analysis: Western blotting and proteomics to correlate transcriptional changes with protein-level alterations.

• In situ hybridization: To localize expression changes within heterogeneous tissues.

• ChIP-Seq analysis: To identify potential transcription factors and genomic regions responding to MOIH-2 signaling.

Data should be analyzed using appropriate statistical methods, including correction for multiple comparisons in genome-wide studies. Pathway enrichment analysis can help identify biological processes affected by MOIH-2 beyond the known effects on methyl farnesoate synthesis.

How can structural modifications be introduced to recombinant MOIH-2 to study structure-function relationships?

Understanding the structure-function relationships of MOIH-2 is crucial for elucidating its mechanism of action. Several methodological approaches can be employed to introduce and study structural modifications:

Site-directed mutagenesis strategies:

• Cysteine substitutions: Systematically replace each of the six conserved cysteines to disrupt specific disulfide bonds and assess the impact on bioactivity.

• Alanine scanning: Replace individual amino acids with alanine to identify residues critical for receptor binding or activation.

• Charge modifications: Alter charged amino acids to investigate electrostatic interactions involved in receptor binding.

• N-terminal and C-terminal truncations: Create progressive truncations to determine minimum bioactive fragments.

• MOIH-1/MOIH-2 chimeras: Create hybrid molecules swapping domains between the two isoforms to identify regions responsible for any functional differences.

Analytical approaches to assess structural changes:

• Circular dichroism spectroscopy: Evaluate secondary structure alterations resulting from modifications.

• Nuclear magnetic resonance (NMR) spectroscopy: Determine three-dimensional structure changes in solution.

• X-ray crystallography: Obtain high-resolution structural data of modified peptides, potentially in complex with receptor fragments.

Functional evaluation of modified peptides:

• In vitro mandibular organ bioassays: Measure inhibition of methyl farnesoate synthesis.

• Receptor binding assays: Quantify changes in binding affinity for putative receptors.

• Signal transduction assays: Assess activation of downstream signaling pathways.

This systematic approach would generate a comprehensive map of structure-function relationships for MOIH-2, potentially identifying specific regions or residues critical for receptor recognition and biological activity.

What are the most promising approaches for identifying the complete signaling pathway of MOIH-2?

Elucidating the complete signaling pathway of MOIH-2 requires an integrated approach targeting multiple levels of the signaling cascade:

• Receptor identification and characterization:

  • Genomic and transcriptomic screening for candidate GPCRs in mandibular organ tissue

  • Heterologous expression systems for functional validation

  • CRISPR-Cas9 receptor knockout studies in model crustaceans

• Second messenger systems:

  • Investigation of cAMP, cGMP, and Ca²⁺ dynamics in response to MOIH-2 stimulation

  • Phosphoproteomic analysis to identify early phosphorylation events

  • Real-time imaging of signaling events using fluorescent biosensors

• Transcription factor activation:

  • ChIP-Seq to identify transcription factors responding to MOIH-2 signaling

  • Analysis of putative Broad Complex Z2 transcription factor elements found in the upstream regions of MOIH genes

  • Motif analysis of promoters of MOIH-2-responsive genes

• Gene regulatory networks:

  • Time-course transcriptomics following MOIH-2 exposure

  • Network analysis to construct hierarchical gene regulation maps

  • Integration with existing knowledge of methyl farnesoate synthesis regulation

• Cross-talk with other hormonal systems:

  • Investigation of interactions between MOIH-2 and other CHH family members

  • Analysis of potential convergence with ecdysteroid signaling pathways

  • Examination of feedback mechanisms regulating MOIH-2 production and release

This multi-level approach would provide a comprehensive understanding of how MOIH-2 signals are transduced from receptor binding to ultimate physiological effects on methyl farnesoate production and crustacean development.

How might recombinant MOIH-2 be applied to address fundamental questions in comparative endocrinology?

Recombinant MOIH-2 offers valuable tools for addressing several fundamental questions in comparative endocrinology:

• Evolution of hormone-receptor specificity:

  • Cross-species bioassays using recombinant Cancer pagurus MOIH-2 on mandibular organs from diverse crustacean species

  • Comparative receptor binding studies across evolutionary distant crustaceans

  • Analysis of selective pressures on MOIH genes across crustacean lineages

• Convergent evolution of juvenile hormone signaling:

  • Comparative analysis of MOIH-2 (regulating methyl farnesoate) and insect allatostatin (regulating juvenile hormone) signaling pathways

  • Investigation of shared downstream targets between methyl farnesoate and juvenile hormone

  • Exploration of the relationship between ITP-like peptides in crabs and insects

• Neuroendocrine network organization and plasticity:

  • Mapping of MOIH-2 neuron connectivity within the complex neuroendocrine system

  • Comparison of differential tissue distribution patterns of CHH family peptides across crustacean species

  • Analysis of how environmental factors reshape neuroendocrine networks

• Hormone multiplicity and subfunctionalization:

  • Investigation of why multiple isoforms of MOIH exist (MOIH-1 and MOIH-2)

  • Examination of tissue-specific responses to different MOIH isoforms

  • Analysis of evolutionary patterns leading to gene duplication and diversification within the CHH family

• Endocrine regulation of life-history transitions:

  • Application of recombinant MOIH-2 to study developmental transitions in crustaceans

  • Investigation of seasonal reproductive cycles and the role of methyl farnesoate

  • Analysis of stress-induced developmental plasticity mediated by MOIH-2 signaling